JP2022547952A5 - - Google Patents
Info
- Publication number
- JP2022547952A5 JP2022547952A5 JP2022515701A JP2022515701A JP2022547952A5 JP 2022547952 A5 JP2022547952 A5 JP 2022547952A5 JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022547952 A5 JP2022547952 A5 JP 2022547952A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl
- pharmaceutically acceptable
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900869P | 2019-09-16 | 2019-09-16 | |
| US201962900860P | 2019-09-16 | 2019-09-16 | |
| US201962900863P | 2019-09-16 | 2019-09-16 | |
| US201962900865P | 2019-09-16 | 2019-09-16 | |
| US62/900,860 | 2019-09-16 | ||
| US62/900,863 | 2019-09-16 | ||
| US62/900,869 | 2019-09-16 | ||
| US62/900,865 | 2019-09-16 | ||
| PCT/US2020/050768 WO2021055295A1 (en) | 2019-09-16 | 2020-09-14 | Brd9 bifunctional degraders and their methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547952A JP2022547952A (ja) | 2022-11-16 |
| JP2022547952A5 true JP2022547952A5 (enExample) | 2023-09-25 |
Family
ID=72915891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515701A Ceased JP2022547952A (ja) | 2019-09-16 | 2020-09-14 | Ｂｒｄ９二機能性分解誘導薬及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220315578A1 (enExample) |
| EP (1) | EP4041724A1 (enExample) |
| JP (1) | JP2022547952A (enExample) |
| KR (1) | KR20220063192A (enExample) |
| CN (1) | CN114641473A (enExample) |
| AU (1) | AU2020349451B2 (enExample) |
| BR (1) | BR112022003514A2 (enExample) |
| CA (1) | CA3153529A1 (enExample) |
| CO (1) | CO2022002842A2 (enExample) |
| CR (1) | CR20220105A (enExample) |
| DO (1) | DOP2022000053A (enExample) |
| EC (1) | ECSP22018571A (enExample) |
| IL (1) | IL290677A (enExample) |
| JO (1) | JOP20220069A1 (enExample) |
| MX (1) | MX2022003102A (enExample) |
| PE (1) | PE20221417A1 (enExample) |
| PH (1) | PH12022550611A1 (enExample) |
| PY (1) | PY2054376A (enExample) |
| TW (1) | TW202123942A (enExample) |
| UY (1) | UY38880A (enExample) |
| WO (1) | WO2021055295A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112236172A (zh) | 2018-01-30 | 2021-01-15 | 福宏治疗公司 | 用于治疗病症的方法和化合物 |
| EP3774804A1 (en) | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160192A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| TWI873185B (zh) | 2019-09-16 | 2025-02-21 | 日商武田藥品工業股份有限公司 | 唑稠合之嗒-3(2h)-酮衍生物 |
| MX2022009308A (es) | 2020-01-29 | 2022-08-22 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| CN115806547A (zh) * | 2021-09-09 | 2023-03-17 | C4医药公司 | 选择的用于brd9的靶向降解的化合物 |
| CN118339151A (zh) * | 2021-12-15 | 2024-07-12 | 西藏海思科制药有限公司 | 一种抑制或降解brd9的化合物及其组合物和药学上的应用 |
| WO2023200800A1 (en) * | 2022-04-11 | 2023-10-19 | Foghorn Therapeutics Inc. | Methods of treating androgen receptor-independent prostate cancer |
| WO2024163609A1 (en) * | 2023-02-01 | 2024-08-08 | Foghorn Therapeutics Inc. | Compositions for treating cancer |
| JP2026519523A (ja) | 2023-05-24 | 2026-06-16 | ビアクティカ セラピューティクス エービー | Ｔｅａｄへの結合剤としての芳香族アミドおよびそのコンジュゲート |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| CN117229202B (zh) * | 2023-11-15 | 2024-01-26 | 苏州美诺医药科技有限公司 | 一种brd9靶向降解化合物的中间体的制备方法 |
| WO2025256550A1 (zh) * | 2024-06-12 | 2025-12-18 | 杭州中美华东制药有限公司 | 靶向降解剂配体及连接基的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| US11285218B2 (en) * | 2016-06-23 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use |
| WO2018064589A1 (en) * | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| US11065231B2 (en) * | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| CN111491933A (zh) * | 2017-12-18 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 具有e3泛素连接酶部分的egfr双功能抑制剂 |
| US11512080B2 (en) * | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| EP3774804A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| WO2020051235A1 (en) * | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| EP3917517A4 (en) * | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2020160192A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
-
2020
- 2020-09-14 TW TW109131573A patent/TW202123942A/zh unknown
- 2020-09-14 JP JP2022515701A patent/JP2022547952A/ja not_active Ceased
- 2020-09-14 PE PE2022000406A patent/PE20221417A1/es unknown
- 2020-09-14 CA CA3153529A patent/CA3153529A1/en active Pending
- 2020-09-14 US US17/020,114 patent/US20220315578A1/en active Pending
- 2020-09-14 WO PCT/US2020/050768 patent/WO2021055295A1/en not_active Ceased
- 2020-09-14 CN CN202080061458.1A patent/CN114641473A/zh active Pending
- 2020-09-14 UY UY0001038880A patent/UY38880A/es not_active Application Discontinuation
- 2020-09-14 BR BR112022003514A patent/BR112022003514A2/pt unknown
- 2020-09-14 MX MX2022003102A patent/MX2022003102A/es unknown
- 2020-09-14 KR KR1020227010572A patent/KR20220063192A/ko not_active Ceased
- 2020-09-14 CR CR20220105A patent/CR20220105A/es unknown
- 2020-09-14 PH PH1/2022/550611A patent/PH12022550611A1/en unknown
- 2020-09-14 EP EP20793192.4A patent/EP4041724A1/en active Pending
- 2020-09-14 AU AU2020349451A patent/AU2020349451B2/en not_active Ceased
- 2020-09-14 PY PY202002054376A patent/PY2054376A/es unknown
-
2022
- 2022-02-16 IL IL290677A patent/IL290677A/en unknown
- 2022-03-10 DO DO2022000053A patent/DOP2022000053A/es unknown
- 2022-03-11 EC ECSENADI202218571A patent/ECSP22018571A/es unknown
- 2022-03-11 CO CONC2022/0002842A patent/CO2022002842A2/es unknown
- 2022-03-15 JO JOP/2022/0069A patent/JOP20220069A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535744A5 (enExample) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2019514883A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2021512059A5 (enExample) | ||
| JP2019514882A5 (enExample) | ||
| CN114430741A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2023529701A5 (enExample) | ||
| JP2024530495A5 (enExample) | ||
| JP2019519476A5 (enExample) | ||
| JP2020518669A5 (enExample) | ||
| JP2021519783A5 (enExample) | ||
| JP2025160318A5 (enExample) | ||
| JP2019514876A5 (enExample) | ||
| JP2011511095A5 (enExample) | ||
| IL311645B1 (en) | 2,5-Dimethomers of 3-methylpyrazines and 2,5,6-Trimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors | |
| CN113365988A (zh) | Shp2抑制剂及其应用 | |
| CN110573501A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2023534528A5 (enExample) | ||
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2007534695A5 (enExample) | ||
| JP2020533280A5 (enExample) | ||
| JP2022526890A5 (enExample) | ||
| CN110582489A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| RU2020102453A (ru) | Фармацевтические композиции |